Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.50 |
| ▸ | CPB1 | P15086 | 3/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408085 | 1.00 | CPB2 (0.52) | CPB2ITGB3ITGA2BCPB1FAAH | |
| SCHEMBL8624147 | 1.00 | CPB2 (0.52) | CPB2ITGB3ITGA2BCPB1FAAH | |
| SCHEMBL21372487 | 1.00 | CPB2 (0.52) | CPB2ITGB3ITGA2BCPB1FAAH | |
| SCHEMBL8625496 | 1.00 | CPB2 (0.52) | CPB2ITGB3ITGA2BCPB1FAAH | |
| SCHEMBL8621283 | 1.00 | CPB2 (0.52) | CPB2ITGB3ITGA2BCPB1FAAH | |
| SCHEMBL8989234 | 1.00 | CPB2 (0.52) | CPB2ITGB3ITGA2BCPB1FAAH | |
| SCHEMBL5964669 | 0.99 | CPB2 (0.53) | CPB2ITGB3ITGA2BCPB1FAAH | |
| SCHEMBL5964745 | 0.96 | CPB2 (0.51) | CPB2ITGB3ITGA2BCPB1FAAH | |
| SCHEMBL8625507 | 0.94 | SLC6A5 (0.53) | CPB2ITGB3ITGA2BCPB1FAAH | |
| SCHEMBL6937530 | 0.92 | CPB2 (0.44) | CPB2ITGB3ITGA2BCPB1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140086855-A1 | COMBINED USE OF A CARNOSINASE INHIBITOR WITH L-CARNOSINE OR ITS RELATED SUBSTANCE AND A COMPOSITION CONTAINING THE SAME | INNOVATIVE VISION PRODUCTS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20060116328-A1 | Combined use of carnosinase inhibitor with l-carnosines and composition | INNOVATIVE VISION PRODUCTS, INC. | 2006-06-01 | — | — | US | disclosed |
| EP-1586332-A1 | COMBINED USE OF CARNOSINASE INHIBITOR WITH L-CARNOSINES AND COMPOSITION | Innovative Vision Products, Inc. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-4342774-A | N-Acylcarnosine aluminum salt, its preparation, and a digestive ulcer remedy containing such salt | NIPPON CHEMIPHAR CO., LTD. (JP) | 1982-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116328-A1 | Combined use of carnosinase inhibitor with l-carnosines and composition | LCT, ADH1C, PON1 | CPB2 550/4885ITGB3 4835/4885ITGA2B 4870/4885 |
| US-20140086855-A1 | COMBINED USE OF A CARNOSINASE INHIBITOR WITH L-CARNOSINE OR ITS RELATED SUBSTANCE AND A COMPOSITION CONTAINING THE SAME | LCT, CPA1, ADH1C | CPB2 379/4885ITGB3 4842/4885ITGA2B 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.